Clinical Research: Principal Investigator
2001-2005 - A phase II randomized, controlled, double-masked, dose-finding, multi-center, comparative trial, in parallel groups, to establish the safety and preliminary efficacy of intravitreal injections of EYE001 (anti-VEGF pegylated aptamer), given every 6 weeks for 12 to 30 weeks to patients with clinically significant macular edema (CSME) involving the center of the macula.
Sponsor: Eyetech Pharmaceuticals, Inc.
2001-present - A phase II/III randomized, double-masked, controlled, dose-ranging, multi- center comparative trial, in parallel groups, to establish the safety and efficacy of intravitreal injections of EYE001 (anti-VEGF pegylated aptamer) given every 6 weeks for 54 weeks, in patients with exudative age-related macular degeneration (AMD).
Sponsor: Eyetech Pharmaceuticals, Inc.
2002-present - A randomized, double-masked, multi-center trial of the safety, tolerability and pharmacokinetics of 1mg/eye and 3 mg/eye intravitreal injections of pegaptanib sodium (anti-VEGF pegylated aptamer) given every 6 weeks for 54 weeks, in patients with exudative age-related macular degeneration (AMD).
Sponsor: Eyetech Pharmaceuticals, Inc.
2003-present - Diabetic Retinopathy Clinical Research Network Protocol 1-A: A pilot study of laser photocoagulation for diabetic macular edema.
Sponsor: JAEB Center
2004-present - An Evaluation of Efficacy and Safety of Posterior Juxtascleral Administrations of Anecortave Acetate for Depot Suspension (15mg or 30mg) versus Sham Administration in Patients (Enrolled in Study “A” or Study “B”) at Risk for Developing Sight Threatning Choroidal Neovascularization (CNV) Due to Exudative Age Related Macular Degeneration (AMD), Protocol Number C-02-60.
Sponsor: Alcon Pharmaceuticals
2004-present - A Phase II prospective, randomized, double-masked, sham-controlled, dose-ranging, multi-center trial to assess the effect of pegaptanib sodium on foveal thickening in patients with exudative subfoveal age-related macular degeneration (AMD).
Sponsor: Eyetech Pharmaceuticals
2004-present - A Phase II randomized, double-masked, multi-center trial, in groups, to determine the safety, efficacy and pharmacokinetics of intravitreous injections of pegaptanib sodium compared to sham injection for 30 weeks in patients with recent vision loss due to macular edema secondary to CRVO.
Sponsor: Eyetech Pharmaceuticals
2004-present - A Phase 1/2 Randomized, Masked, Single and Multiple-Dose, Sequential Dose-Escalation Study of the Safety and Efficacy of AG-013958 in Subjects with Subfoveal Choroidal Neovascularization Associated with Age-related Macular Degeneration
Sponsor: Pfizer Inc.
2004-present - A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Laser Photocoagulation for Diabetic Macular Edema to determine whether intravitreal triamcinolone injections at doses of 1 mg or 4 mg produce greater benefit, with an acceptable safety profile, than macular laser photocoagulation in the treatment of diabetic macular edema and will also compare the efficacy and safety of the 1 mg and 4 mg triamcinolone doses
Sponsor: Diabetic Retinopathy Clinical Research Network
2004-present - The Standard Care vs. Corticosteroid for Retinal Vein Occlusion Study. Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide with Standard Care to Treat Macular Edema: One for Central Retinal Vein Occlusion and One for Branch Retinal Vein Occlusion (SCORE Study)
Sponsor: National Eye Institute
2005-present - A phase 4, randomized, active controlled, double masked, single dummy, multi-center comparative trial, in parallel groups, to compare the safety and efficacy of intravitreous injections of Macugen given every 6 weeks for up to 102 weeks, plus sham photodynamic therapy (PDT), to Macugen plus PDT with Visudyne in subjects with predominantly classic subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)
Sponsor: Eyetech Pharmaceuticals
2005-present - DRCR Protocol C: Temporal variation in optical coherence tomography measurements of retinal thickening in diabetic macular edema
Sponsor: Diabetic Retinopathy Clinical Research Network.
Clinical Research: Sub-Investigator
2003-present - A phase III, multicenter, randomized, double-masked, active treatment-controlled study of the efficacy and safety of rhuFab (ranibizumab) compared with Verteporfin (Visudyne) photodynamic therapy in subjects with predominantly classic subfoveal neovascular age-related macular degeneration.
Sponsor: Genentech
2004-present - A Six-Month Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial (with Six-Month Open-Label Extension) to Assess the Safety and Efficacy of 700ug and 350ug Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS Applicator System) in the Treatment of Patients with Macular Edema Following Central Retinal Vein Occlusion or Branch Retinal Vein Occlusion
Sponsor: Allergan
Collaborating Physician
2002-present - Study of Diabetic Retinopathy in the Family Investigation of Nephropathy and Diabetes (FIND)
Sponsor: National Eye Institute
